Dicerna Pharma (DRNA) Tops Q3 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts DRNA Hot Sheet
Join SI Premium – FREE
Dicerna Pharma (NASDAQ: DRNA) reported Q3 EPS of ($0.22), $0.24 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $63 million versus the consensus estimate of $43.78 million.
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Robinhood (HOOD) Tops Q3 EPS by 5c, Misses on Revenue
- Franklin Street Properties (FSP) Misses Q3 EPS by 1c
- National Bank Holdings (NBHC) Misses Q3 EPS by 102c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
